What Happened?

Shares of animal health company Elanco (NYSE:ELAN) jumped 21.2% in the afternoon session after the company reported decent first quarter 2025 results which beat analysts' EPS expectations and included constant currency revenue outperformance. Organic sales were up 4%, thanks to strong demand in cattle health and good traction from new pet meds like Credelio Quattro. Even though sales were flat, operating margins improved, a sign they're managing prices and costs pretty well.

On the other hand, its full-year EBITDA guidance missed. Overall, we think this was a decent quarter with some key metrics above expectations.

The shares closed the day at $12, up 26.2% from previous close.

Is now the time to buy Elanco? Access our full analysis report here, it’s free.

What The Market Is Telling Us

Elanco’s shares are quite volatile and have had 16 moves greater than 5% over the last year. But moves this big are rare even for Elanco and indicate this news significantly impacted the market’s perception of the business.

Investors who bought $1,000 worth of Elanco’s shares 5 years ago would now be looking at an investment worth $606.14.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

View Comments